

Letters to the editor

Prediction of antidepressant response

L Colonna, M Zann

CHU Charles Nicolle, 1 rue de Germont, 76301 Rouen, France

(Received 12 September 1995; accepted 21 September 1995)

In an article published in *European Psychiatry*, Stassen et al (1994) concentrated on the first signs of improvement observed during the course of treatment of a depressive state where early improvement might indicate a favourable response to later treatment. Their conclusions come from a meta-analysis of 11 studies involving 1,277 patients. We would like to put forward some observations concerning their findings.

Although the idea of estimating early on the therapeutic response (of treatment) and determining from this predictive elements of a later favourable response appeared interesting to us, several of the conclusions drawn however seem to us as somewhat ambiguous.

The first conclusion that the authors draw is that the beginning of improvement among responsive patients from day 3 up to day 28 (either a partial or complete response) follows a near identical progression whether the placebo or one of the active products (imipramine or moclobemide) is used. This observation, if confirmed, would not favour a specific action on the part of the antidepressant compared to the placebo, at least as far as its kinetic aspect is concerned. The antidepressant would only differ from the placebo by a superior number of patients responding to the treatment.

As far as the predictive effect of treatment during the course of the first week is concerned, the meta-analysis conducted by the authors has only in fact indicated an inverse correlation: 70% of responsive patients would show signs of early improvement. This assertion has little practical significance and the lack of information concerning the non-responsive patients or those only showing a partial response to treatment is a strong limiting factor. In their analysis of more than 1,000 patients, the authors do indeed show that 118 patients whose state was initially improved by imipramine did not become responding patients and that within the moclobemide group, 231 patients did not improve further either, in spite of early positive signs.

In their discussion, the authors deny specific effectiveness to the antidepressants "*the therapeutic qualities of these drugs do not consist in suppression of symptoms, but rather relate to their ability to elicit and maintain certain conditions which enable recovery. The time course of recovery becomes identical to spontaneous, natural remission of depressive episode*".

However, the absence of clinical qualitative study along with the lack of a study concerning the non-responsive patients does not seem to us to permit the drawing of a definitive conclusion. The authors have in fact kept as a criteria or evaluation Hamilton's depression scale and have considered the different percentages of improvement likely to be chosen to define response to treatment. The meta-analysis did not allow them to conduct a qualitative study of depressive symptomatology. This analysis could prove useful in distinguishing the different types of early response to treatment; the one which would predict a later response, then recovery or that which would just lead to a partial remission, or would not be confirmed during later evaluations.

We can therefore form the hypothesis that the early stages of improvement in a depressive state could on the one hand concern the specific components of a depressive state but on the other hand could only concern the non-specific symptoms (disturbed sleep, loss of appetite, somatic problems etc). The early improvement of specific problems seems to us to be a stronger predicting factor than the improvement of 'peripheral' problems of depression. We would be interested in having the author's opinion on the above comments.

Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression. Meta-analysis of improvement and moclobemide versus placebo. *Eur Psychiatry* 1994;9:129–36

Dietary interferences with lithium therapy

P Castrogiovanni, F Pieraccini

Universita' Degli Studi di Siena, Istituto di Clinica delle Malattie Nervose e Mentali, Cattedra di Psichiatria, P.zza Duomo, 2, 53100 Siena, Italy

(Received 29 August 1995; accepted 19 September 1995)

Variations of serum lithium concentrations are known in patients treated with lithium carbonate. These variations are frequently connected with some variables we know to influence serum lithium concentrations (variations of dosage, entity of sodium chloride in the diet, concomitant therapies, etc). Regarding this issue, we describe a case suggesting a variability factor, which even already considered, might be underestimated in clinical practice.

GP is a 56 year-old married woman without somatic diseases, with a long history of bipolar I disorder (predominantly manic, without psychotic features), treated